Saluda Medical has announced that it has received US$10 million in Series B financing bringing a breakthrough treatment for chronic pain one step closer to reality.
The company, a successful spin-out from NICTA, Australia’s Information Communications and Technology (ICT) Research Centre of Excellence, is developing world-first neuromodulation technologies that will improve the treatment of chronic pain, Parkinson’s disease, epilepsy and other debilitating disorders.
Neuromodulation generates therapeutic nerve activity through the delivery of electrical stimulation to targeted sites in the body. Saluda is developing a neuromodulation device that measures nerve signals and adjusts stimulation in real time to achieve optimal outcomes for patients. With 1.5 billion people suffering from chronic pain worldwide, Saluda’s research will bring an increased quality of life to many across the globe.
New investor Biosciences Managers led the funding round, in which existing investors also participated. Saluda intends to use the funds to conduct chronic clinical trials and support commercialisation plans for its Evoke spinal cord stimulation system to treat chronic pain of the trunk and limbs.
Saluda chief executive officer John Parker comments: “We are delighted to welcome Biosciences Managers as a key shareholder. Their knowledge and experience in the world of medical devices will complement our extraordinary group of existing investors to support Saluda through its next phases of evolution.”
“With the new funding support we are able to open the next chapter of research into chronic pain, bringing us closer to commercialising a revolutionary treatment that promises to help many people,” continue Parker.